(13E)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[1-(3-phenyloxiran-2-yl)ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone (BioDeep_00000911369)
代谢物信息卡片
化学式: C36H45ClN2O8 (668.2864280000001)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)CC1C(=O)OC(CC=CC(=O)NC(C(=O)NCC(C(=O)O1)(C)C)CC2=CC(=C(C=C2)OC)Cl)C(C)C3C(O3)C4=CC=CC=C4
InChI: InChI=1S/C36H45ClN2O8/c1-21(2)17-29-34(42)45-27(22(3)31-32(47-31)24-11-8-7-9-12-24)13-10-14-30(40)39-26(19-23-15-16-28(44-6)25(37)18-23)33(41)38-20-36(4,5)35(43)46-29/h7-12,14-16,18,21-22,26-27,29,31-32H,13,17,19-20H2,1-6H3,(H,38,41)(H,39,40)/b14-10+
描述信息
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents
D050258 - Mitosis Modulators
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ramesh R Boinpally, Lisa Polin, Sen-Lin Zhou, Bhaskara R Jasti, Richard A Wiegand, Kathryn White, Juiwanna Kushner, Jerome P Horwitz, Thomas H Corbett, Ralph E Parchment. Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
Cancer chemotherapy and pharmacology.
2003 Jul; 52(1):25-33. doi:
10.1007/s00280-003-0621-0. [PMID: 12739061] - C Sessa, K Weigang-Köhler, O Pagani, G Greim, O Mora, T De Pas, M Burgess, I Weimer, R Johnson. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
European journal of cancer (Oxford, England : 1990).
2002 Dec; 38(18):2388-96. doi:
10.1016/s0959-8049(02)00489-6. [PMID: 12460783] - James P Stevenson, Weijing Sun, Maryann Gallagher, Robert Johnson, David Vaughn, Lynn Schuchter, Kenneth Algazy, Stephen Hahn, Nathan Enas, Diane Ellis, Donald Thornton, Peter J O'Dwyer. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2002 Aug; 8(8):2524-9. doi:
. [PMID: 12171879] - D Kessel. Protein-binding patterns of the antitumor antibiotic cryptophycin 52 as measured with a two-phase partitioning system.
Journal of chromatography. B, Biomedical sciences and applications.
1999 Nov; 735(1):121-6. doi:
10.1016/s0378-4347(99)00404-1. [PMID: 10630897] - R M Schultz, C Shih, P G Wood, S D Harrison, W J Ehlhardt. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Oncology reports.
1998 Sep; 5(5):1089-94. doi:
10.3892/or.5.5.1089. [PMID: 9683814]